91 related articles for article (PubMed ID: 8183553)
1. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines.
Sekido Y; Bader S; Latif F; Gnarra JR; Gazdar AF; Linehan WM; Zbar B; Lerman MI; Minna JD
Oncogene; 1994 Jun; 9(6):1599-604. PubMed ID: 8183553
[TBL] [Abstract][Full Text] [Related]
2. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.
Shigemitsu K; Sekido Y; Usami N; Mori S; Sato M; Horio Y; Hasegawa Y; Bader SA; Gazdar AF; Minna JD; Hida T; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Shimokata K
Oncogene; 2001 Jul; 20(31):4249-57. PubMed ID: 11464291
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer.
Sekido Y; Pass HI; Bader S; Mew DJ; Christman MF; Gazdar AF; Minna JD
Cancer Res; 1995 Mar; 55(6):1227-31. PubMed ID: 7882313
[TBL] [Abstract][Full Text] [Related]
4. Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer.
Hensel CH; Xiang RH; Sakaguchi AY; Naylor SL
Oncogene; 1991 Jun; 6(6):1067-71. PubMed ID: 1648702
[TBL] [Abstract][Full Text] [Related]
5. Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer.
Waber PG; Lee NK; Nisen PD
Oncogene; 1996 Jan; 12(2):365-9. PubMed ID: 8570213
[TBL] [Abstract][Full Text] [Related]
6. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
Lerman MI; Minna JD
Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
[TBL] [Abstract][Full Text] [Related]
7. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions.
Cairns P; Okami K; King P; Bonacum J; Ahrendt S; Wu L; Mao L; Jen J; Sidransky D
Cancer Res; 1997 Dec; 57(23):5356-9. PubMed ID: 9393760
[TBL] [Abstract][Full Text] [Related]
8. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer.
Wu W; Kemp BL; Proctor ML; Gazdar AF; Minna JD; Hong WK; Mao L
Cancer Res; 1999 Apr; 59(8):1846-51. PubMed ID: 10213490
[TBL] [Abstract][Full Text] [Related]
9. KLF6: mutational analysis and effect on cancer cell proliferation.
Yin D; Komatsu N; Miller CW; Chumakov AM; Marschesky A; McKenna R; Black KL; Koeffler HP
Int J Oncol; 2007 Jan; 30(1):65-72. PubMed ID: 17143513
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
Kley N; Whaley J; Seizinger BR
Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
[TBL] [Abstract][Full Text] [Related]
11. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
12. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens.
Zhuang Z; Gnarra JR; Dudley CF; Zbar B; Linehan WM; Lubensky IA
Mod Pathol; 1996 Aug; 9(8):838-42. PubMed ID: 8871925
[TBL] [Abstract][Full Text] [Related]
13. Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line.
Nishioka M; Kohno T; Takahashi M; Niki T; Yamada T; Sone S; Yokota J
Oncogene; 2000 Dec; 19(54):6251-60. PubMed ID: 11175339
[TBL] [Abstract][Full Text] [Related]
14. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
[TBL] [Abstract][Full Text] [Related]
16. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
Shuin T; Kondo K; Torigoe S; Kishida T; Kubota Y; Hosaka M; Nagashima Y; Kitamura H; Latif F; Zbar B
Cancer Res; 1994 Jun; 54(11):2852-5. PubMed ID: 8187067
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis.
Cario H; Schwarz K; Jorch N; Kyank U; Petrides PE; Schneider DT; Uhle R; Debatin KM; Kohne E
Haematologica; 2005 Jan; 90(1):19-24. PubMed ID: 15642664
[TBL] [Abstract][Full Text] [Related]
18. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
20. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L
Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
